Filing Details

Accession Number:
0001415889-21-004885
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-15 18:44:40
Reporting Period:
2021-10-14
Accepted Time:
2021-10-15 18:44:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750284 Olema Pharmaceuticals Inc. OLMA Pharmaceutical Preparations (2834) 300409740
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1831218 Sean Bohen C/O Olema Pharmaceuticals, Inc.
512 2Nd Street, 4Th Floor
San Francisco CA 94107
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-10-14 5,000 $4.82 57,514 No 4 M Direct
Common Stock Disposition 2021-10-14 4,649 $30.42 52,865 No 4 S Direct
Common Stock Disposition 2021-10-14 351 $31.17 52,514 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-10-14 5,000 $0.00 5,000 $4.82
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
966,316 2030-11-18 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  2. The weighted average sale price for the transaction reported was $30.42, and the range of prices were between $30.00 and $30.99. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. The weighted average sale price for the transaction reported was $31.17, and the range of prices were between $31.00 and $31.28. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  4. (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable.